ABSTRACT
Objective To explore the effects of pitavastatin and atorvastatin on blood lipids and fasting blood glucose (FBG) in patients with premature coronary artery disease (PCAD) with acute myocardial infarction (AMI). Methods One hundred forty-six patients met the diagnostic criteria of PCAD with AMI were chosen from Aug. 2018 to Apr. 2019 in the Department of Cardiology of the First Affiliated Hospital of Jinzhou Medical University, and randomized into pitavastatin group (pitavastatin calcium dispersible tablets, 2 mg/d) and atorvastatin group (atorvastatin calcium capsules, 20 mg/d). Patients in both groups were treated for 3 months. The levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and FBG 1- and 3-month after treatment in the two groups were then observed and compared. Results Before treatment, no significant difference existed in TC, TG, HDL and LDL between the two groups (P>0.05). While 1- and 3-month after treatment, in pitavastatin group the level of TC was lower than that before treatment [(3.80±0.78) mmol/L and (3.78±0.76) mmol/L vs. (4.55±1.12) mmol/L], of TG was lower than that before treatment [(1.41±0.56) mmol/L and (1.21±0.42) mmol/L vs. (1.85±1.05) mmol/L], of LDL was lower than that before treatment [(2.21±0.75) mmol/L and (2.18±0.67) mmol/L vs. (2.97±0.81) mmol/L], but of HDL was higher than that before treatment [(1.08±0.20) mmol/L and (1.16±0.24) mmol/L vs. (1.02±0.24) mmol/L], and the differences were statistically significant (P0.05). Before treatment, no significant difference existed in the level of FBG between the two groups (P>0.05). The FBG level in pitavastatin group showed no significant difference (P>0.05) 1- and 3-month after treatment (5.33±0.90 mmol/L and 5.37±0.60 mmol/L) compared with that before treatment (5.34±0.53 mmol/L). While in atorvastatin group, the level of FBG was higher 1- and 3-month after treatment than that before treatment (5.64±0.73 mmol/L, 5.70±0.91 mmol/L vs. 5.26±0.61 mmol/L), and the difference was statistically significant (P<0.05). One- and 3-month after treatment, the level of FBG was higher in atorvastatin group than that in pitavastatin group with significant differences (P<0.05). Conclusions Pitavastatin can ameliorate the blood lipids levels effectively in patients of PCAD with AMI without affecting the FBG. Therefore, pitavastatin can be used as the first choice of statins in clinic.